Frontlight ResearchEarly access
Graves' disease and hyperthyroidism trials in Poland
6 of 6 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 15 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.
- Where
- Bydgoszcz, Chrzanów, Cracow, Gliwice, Katowice, Krakow, Lodz, Lublin, Opole, Warsaw, Warszawa, Zamość
- Age
- 18 years and over
- People
- 230 worldwide
- Run by
- argenx
See details and how to joinNCT07596849 · EU 2025-523333-26-00 - Phase 2Taking peopleA Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
- Where
- Bialystok, Bydgoszcz, Chorzow, Kielce, Lublin, Olsztyn, Opole, Poznan, Szczecin, Warsaw, Wroclaw
- Age
- 18 years to 75 years
- People
- 210 worldwide
- Run by
- Immunovant Sciences GmbH
See details and how to joinNCT07018323 · EU 2025-521920-31-00 - Phase 2Enrolling by invitationA Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)
- Where
- Bydgoszcz, Kielce, Lublin, Warsaw
- Age
- 18 years and over
- People
- 372 worldwide
- Run by
- Immunovant Sciences GmbH
See details and how to joinNCT07286006 - Phase 2Taking peopleA Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
- Where
- Cracow, Gliwice, Krakow, Lublin, Poznan, Warsaw
- Age
- 18 years to 75 years
- People
- 240 worldwide
- Run by
- Immunovant Sciences GmbH
See details and how to joinNCT06727604 · EU 2024-516020-33-00 - Phase 2Taking peopleA Long-Term Extension Study of IMVT-1402 in Adult Patients With Graves' Disease
- Where
- Bialystok, Bydgoszcz, Chorzow, Cracow, Gliwice, Kielce, Krakow, Lublin, Olsztyn, Opole, Poznan, Szczecin, Warsaw, Wroclaw
- Age
- 18 years and over
- People
- 128 worldwide
- Run by
- Immunovant Sciences GmbH
See details and how to join2025-524001-33-00 - Phase 2Taking peopleAn Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease
- Where
- Warsaw
- Age
- 18 years to 99 years
- People
- 30 worldwide
- Run by
- Amgen
See details and how to joinNCT07438405